➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Merck
Medtronic
AstraZeneca
Moodys

Last Updated: September 22, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ENASIDENIB MESYLATE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for enasidenib mesylate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03683433 Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation Recruiting National Cancer Institute (NCI) Phase 2 2018-09-18 This phase II trial studies how well enasidenib and azacitidine work in treating patients with IDH2 gene mutation and acute myeloid leukemia that has come back or does not respond to treatment. Enasidenib and azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
NCT03683433 Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation Recruiting M.D. Anderson Cancer Center Phase 2 2018-09-18 This phase II trial studies how well enasidenib and azacitidine work in treating patients with IDH2 gene mutation and acute myeloid leukemia that has come back or does not respond to treatment. Enasidenib and azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
NCT03825796 CPX-351 and Enasidenib in Treating Patients With Relapsed Acute Myeloid Leukemia Characterized by IDH2 Mutation Not yet recruiting National Cancer Institute (NCI) Phase 2 2019-03-01 This phase II trial studies how well CPX-351 and enasidenib work in treating patients with acute myeloid leukemia characterized by IHD2 mutation that has come back. Drugs used in chemotherapy, such as CPX-351, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Enasidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving CPX-351 and enasidenib may work better in treating patients with acute myeloid leukemia.
NCT03825796 CPX-351 and Enasidenib in Treating Patients With Relapsed Acute Myeloid Leukemia Characterized by IDH2 Mutation Not yet recruiting Jonsson Comprehensive Cancer Center Phase 2 2019-03-01 This phase II trial studies how well CPX-351 and enasidenib work in treating patients with acute myeloid leukemia characterized by IHD2 mutation that has come back. Drugs used in chemotherapy, such as CPX-351, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Enasidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving CPX-351 and enasidenib may work better in treating patients with acute myeloid leukemia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for enasidenib mesylate

Condition Name

Condition Name for enasidenib mesylate
Intervention Trials
Recurrent Acute Myeloid Leukemia 3
IDH2 Gene Mutation 2
Refractory Acute Myeloid Leukemia 2
Chronic Myelomonocytic Leukemia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for enasidenib mesylate
Intervention Trials
Leukemia 3
Leukemia, Myeloid, Acute 3
Leukemia, Myeloid 3
Myelodysplastic Syndromes 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for enasidenib mesylate

Trials by Country

Trials by Country for enasidenib mesylate
Location Trials
United States 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for enasidenib mesylate
Location Trials
California 1
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for enasidenib mesylate

Clinical Trial Phase

Clinical Trial Phase for enasidenib mesylate
Clinical Trial Phase Trials
Phase 2 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for enasidenib mesylate
Clinical Trial Phase Trials
Not yet recruiting 2
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for enasidenib mesylate

Sponsor Name

Sponsor Name for enasidenib mesylate
Sponsor Trials
National Cancer Institute (NCI) 3
Children's Oncology Group 1
Jonsson Comprehensive Cancer Center 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for enasidenib mesylate
Sponsor Trials
NIH 3
Other 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Dow
Colorcon
Baxter
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.